The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy
Introduction The pathophysiology of heart failure involves activation of several neurohormonal systems including the renin-angiotensin-aldosterone system. The mineralocorticoid receptor antagonist spironolactone has been shown to be beneficial in humans and dogs with heart failure. The objective of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/48948/ |
| _version_ | 1848797886356127744 |
|---|---|
| author | James, Rachel Guillot, Emilie Garelli-Paar, Catherine Huxley, Jacqueline Grassi, Vanessa Cobb, Malcolm |
| author_facet | James, Rachel Guillot, Emilie Garelli-Paar, Catherine Huxley, Jacqueline Grassi, Vanessa Cobb, Malcolm |
| author_sort | James, Rachel |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Introduction
The pathophysiology of heart failure involves activation of several neurohormonal systems including the renin-angiotensin-aldosterone system. The mineralocorticoid receptor antagonist spironolactone has been shown to be beneficial in humans and dogs with heart failure. The objective of this pilot study was to investigate the efficacy and safety of spironolactone in cats with heart failure secondary to cardiomyopathy already treated with furosemide and an angiotensin-converting enzyme inhibitor.
Animals
Twenty cats with heart failure due to cardiomyopathy.
Methods
The study was a double-blind, randomised, placebo-controlled, multicentre clinical study assessing the effect of spironolactone on survival and clinical parameters in cats with heart failure due to cardiomyopathy. The primary end point was mortality, defined as death (spontaneous or by euthanasia) due to cardiac causes.
Results
Twenty cats were enrolled: 9 in the spironolactone group and 11 in the placebo group of which 56% (5/9) and 0% (0/11) completed the 15-month period respectively. At inclusion, differences in systemic blood pressure, body condition score, electrocardiographic abnormalities and LA/Ao ratio suggested that disease may be less severe in the spironolactone group. Twenty-two percent (2/9) of cats in the spironolactone group and 82% (9/11) in the control group reached the primary end point (Fisher's exact test, p = 0.0216). No safety issues were identified in either group.
Conclusions
This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy. |
| first_indexed | 2025-11-14T20:11:00Z |
| format | Article |
| id | nottingham-48948 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T20:11:00Z |
| publishDate | 2018 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-489482018-12-23T04:30:14Z https://eprints.nottingham.ac.uk/48948/ The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy James, Rachel Guillot, Emilie Garelli-Paar, Catherine Huxley, Jacqueline Grassi, Vanessa Cobb, Malcolm Introduction The pathophysiology of heart failure involves activation of several neurohormonal systems including the renin-angiotensin-aldosterone system. The mineralocorticoid receptor antagonist spironolactone has been shown to be beneficial in humans and dogs with heart failure. The objective of this pilot study was to investigate the efficacy and safety of spironolactone in cats with heart failure secondary to cardiomyopathy already treated with furosemide and an angiotensin-converting enzyme inhibitor. Animals Twenty cats with heart failure due to cardiomyopathy. Methods The study was a double-blind, randomised, placebo-controlled, multicentre clinical study assessing the effect of spironolactone on survival and clinical parameters in cats with heart failure due to cardiomyopathy. The primary end point was mortality, defined as death (spontaneous or by euthanasia) due to cardiac causes. Results Twenty cats were enrolled: 9 in the spironolactone group and 11 in the placebo group of which 56% (5/9) and 0% (0/11) completed the 15-month period respectively. At inclusion, differences in systemic blood pressure, body condition score, electrocardiographic abnormalities and LA/Ao ratio suggested that disease may be less severe in the spironolactone group. Twenty-two percent (2/9) of cats in the spironolactone group and 82% (9/11) in the control group reached the primary end point (Fisher's exact test, p = 0.0216). No safety issues were identified in either group. Conclusions This study suggests that spironolactone is well tolerated, and preliminary results support further investigation to evaluate the efficacy of spironolactone in the treatment of cats with cardiac failure due to cardiomyopathy. Elsevier 2018-02-28 Article PeerReviewed application/pdf en cc_by_nc_nd https://eprints.nottingham.ac.uk/48948/1/SEISICATefficacy.pdf James, Rachel, Guillot, Emilie, Garelli-Paar, Catherine, Huxley, Jacqueline, Grassi, Vanessa and Cobb, Malcolm (2018) The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy. Journal of Veterinary Cardiology, 20 (1). pp. 1-12. ISSN 1875-0834 Aldosterone; Feline; Mineralocorticoid receptor http://www.sciencedirect.com/science/article/pii/S1760273416301060 doi:10.1016/j.jvc.2017.11.001 doi:10.1016/j.jvc.2017.11.001 |
| spellingShingle | Aldosterone; Feline; Mineralocorticoid receptor James, Rachel Guillot, Emilie Garelli-Paar, Catherine Huxley, Jacqueline Grassi, Vanessa Cobb, Malcolm The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title | The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title_full | The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title_fullStr | The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title_full_unstemmed | The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title_short | The SEISICAT study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| title_sort | seisicat study: a pilot study assessing 1 efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy |
| topic | Aldosterone; Feline; Mineralocorticoid receptor |
| url | https://eprints.nottingham.ac.uk/48948/ https://eprints.nottingham.ac.uk/48948/ https://eprints.nottingham.ac.uk/48948/ |